枳术宽中胶囊治疗功能性消化不良餐后不适综合征患者:多中心、随机、双盲、安慰剂对照、平行组临床试验的研究方案
本研究为多中心、随机、患者与研究者双盲、安慰剂对照、平行组临床试验,计划在中国和澳大利亚18家医院招募符合罗马IV诊断标准的功能性消化不良餐后不适综合征(FD-PDS)患者480例,按1:1随机分为枳术宽中胶囊(ZZKZ)组或安慰剂组,治疗8周并随访4周。主要终点为患者自评的餐后饱胀和早饱症状不适程度视觉模拟评分(VAS),每日记录,每周7天。主要分析比较治疗8周前后两组FD-PDS VAS评分应答率,检验水准α=0.05(双侧)。
要点
- 多中心、随机、双盲、安慰剂对照、平行组试验,计划纳入480例FD-PDS患者,1:1随机分组。
- ZZKZ组与安慰剂组均治疗8周并随访4周,主要终点为餐后饱胀和早饱不适VAS评分的应答率。
- 主要分析比较治疗8周前后两组VAS评分应答率,α=0.05(双侧)。
核心结论
- 本试验旨在为已上市产品枳术宽中胶囊(ZZKZ)治疗功能性消化不良餐后不适综合征(FD-PDS)的有效性和安全性强化证据。
- 与既往针对FD-PDS的临床试验相比,本试验设置8周双盲治疗期,通过与安慰剂组比较探讨长期用药的效果。
研究设计与样本
- 多中心、随机、患者与研究者双盲、安慰剂对照、平行组临床试验。
- 计划在中国和澳大利亚18家医院招募符合罗马IV诊断标准的FD-PDS患者,共480例合格患者按1:1随机分为ZZKZ组或安慰剂组。
- 治疗8周,随访4周。
- 主要终点为患者自评的餐后饱胀和早饱症状不适程度视觉模拟评分(VAS),每日记录,每周7天。
- 主要分析比较治疗8周前后两组FD-PDS VAS评分应答率,检验水准α=0.05(双侧)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Functional dyspepsia (FD) is one of the most common functional gastrointestinal disorders. Based on the various symptoms present in patients with functional dyspepsia postprandial distress syndrome (FD-PDS), routine agents such as acid suppressants, prokinetic drugs, and centrally acting drugs, offer limited treatment choices with potential side effects. As a preliminary clinical trial showed that the marketed product Zhizhu Kuanzhong Capsule (ZZKZ) can improve symptoms in FD-PDS patients, our study aims to provide further evidence on the clinical efficacy and safety of ZZKZ in the treatment of patients with FD-PDS. METHODS: In this multicenter, randomized, patient- and investigator-blinded, placebo-controlled, parallel-group clinical trial, we will recruit patients with FD-PDS from 18 hospitals in China and Australia. The trial will enroll patients with FD-PDS based on the Rome IV diagnostic criteria. A total of 480 eligible patients will be randomized 1:1 into either ZZKZ or placebo group with 8 weeks of treatment and 4 weeks of follow-up. The primary endpoint will be measured by a self-rated Visual Analogue Score (VAS) for the degree of discomfort with both symptoms of postprandial fullness and early satiation, recorded once a day and 7 days a week. The primary analysis will aim to compare the response rate for FD-PDS VAS score between the groups before and after 8 weeks of treatment with an alpha level of 0.05 (2-sided). DISCUSSION: This trial aims to strengthen the evidence for the efficacy and safety of ZZKZ, a marketed product, in treating FD-PDS. Compared to the previous clinical trial that targeted FD-PDS, this trial will have an 8-week double-blind treatment period to investigate the effect of long-term mediation through comparison with the placebo group. TRIAL REGISTRATION: ClinicalTrials.gov NCT03825692 . Registered on 28 January 2019.
引用
- Xiao M, Zhong LLD, Lam WC, et al. Zhizhu Kuanzhong Capsule in treating patients with functional dyspepsia postprandial distress syndrome: study protocol for a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. Trials. 2022. PMID: 35655286. doi:10.1186/s13063-022-06396-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。